Biosimilars Market - Forecast(2019 - 2024)

Report Code: HCR 0060 Report Format: PDF + Excel Database
Biosimilars Market Overview

Biosimilars are the copied and licensed versions of the patent-expired reference biologics. Different regulatory bodies such as the EMA and FDA actively regulate the marketing and development of biosimilars. The increase in the prevalence of chronic diseases and the development of innovative Biosimilars with enhanced features present huge business opportunities for the Biosimilars market. The market has been segmented on the basis of product type, technology, and application. The global Biosimilars market is estimated to grow at a CAGR of 37.81% during the forecast period 2018–2023. North America is the fastest growing market with a CAGR of 52.36%, which can be mainly attributed to the increase in FDA approvals in this region.

Biosimilars Market Outlook

The global market for Biosimilars has been demonstrating a brisk growth in recent years owing to the increasing frequency of chronic diseases and technological development of Biosimilars with enhanced applications. Based on product type, Recombinant Glycosylated Protein will witness major growth as Glycosylation is one of the most promising methods among the chemical modification methods for proteins and the desired protein's molecular stability can be achieved through glycosylation. On the basis of technology, the monoclonal antibodies segment is poised to dominate the market, growing at a CAGR of 38.97% during the forecast period. Based on applications of Biosimilars, the oncology disease segment will record major growth during the forecast period 2018–2023.  

Biosimilars Market Growth Drivers 

The Market is largely driven by the growing awareness and low cost of biosimilars. The patent cliff of biologics is also one of the factors that is contributing to the growth of the market. Increased manufacturing capabilities and reduced R & D cost with a positive outcome in clinical trials are acting as a major booster to the market. Rising prevalence of chronic diseases such as cancer and diabetes are also enhancing the market.

Biosimilars Market Challenges 

Complex manufacturing processes, high cost of development, and limited obtainability of biosimilar products are responsible for hindering the growth of this market to a large extent. The safety and efficacy of products pose serious questions and could hinder the market growth to a certain extent.

Biosimilars Market

Biosimilars Market Research Scope

The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of biosimilars that will be used for various kind of treatment. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of Biosimilars product and their specific applications in different types of treatments.

Biosimilars Market Report: Industry Coverage

By Product Type: Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, and Peptides.

By Technology: Monoclonal Antibody Technology, Recombinant DNA Technology.

By Application: Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiency and Others. 

The Biosimilars market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

  • North America: The U.S., Canada, Mexico
  • Europe: The U.K., France, Italy, Germany, Spain, Russia, , Rest of Europe
  • APAC: China, Japan, India, Australia , South Korea, Taiwan, Rest of APAC
  • RoW: South America, Middle East and Africa

Biosimilars Market Trends

  • Rising prevalence of diabetes, anaemia, and other chronic diseases continues to rise. Thus, the demand for cost-effective biosimilar drugs to treat these conditions will continue to increase.
  • Many companies are planning to invest in R&D towards the development of new and innovative Biosimilars. This will open  up more opportunities for the Biosimilars market because of the patent expiration of biologics. 
  • People will be shifting towards Biosimilars because of the low cost associated with them. In the U.S.
  • Healthcare spending is on the rise, and much of the increased expenditure is due to rising drug costs. Thus, it is more likely that people will search for alternatives, and Biosimilars seems to be a good option to them. 

 Key Questions Addressed in the Biosimilars Market Report
1. Is the Biosimilars market growing? How long will it continue to grow and at what rate? 
2. Which type of Biosimilars presents the major growth opportunities? 
3. Is there a possibility for change in the market structure over time? 
4. Are additional developments needed for the existing product or services offerings or do the existing products meet the customer demands? 
5. Do the key vendors look for partnerships to expand their businesses with respect to geography or product? 
6. What is the current status of Biosimilars in different countries?  
7. Which type of Biosimilars will witness heavy adoption in the near future? 
8. What are the short-term, long-term, and medium-term growth drivers for the market? 
9. What are the short-term, medium-term, and long-term challenges for the market? 
10. What are the short-term, medium-term, and long-term opportunities for the market?
11. Who are the top players/companies of the market? 
12. What are the recent innovations in the market? 
13. How many patents have been filed by the leading players? 
14. What are the types of patents filed by the leading players? 
15. What is the futuristic scenario for the adoption of Biosimilars? 
16. What is our Vision 2030 for the Biosimilars market?

A few focus points of this Research are given below:

  • Give a deep-dive analysis of the key operational strategies with focus on the corporate structure, R&D strategies, localization strategies, production capabilities, and sales performance of various companies.
  • Provide an overview of the product portfolio, including product planning, development, and positioning.
  • Discuss the role of technology companies in partnerships.
  • Explore the regional sales activities.
  • Analyze the market size and giving the forecast for current and future global Biosimilars market during the forecast 2018–2023.
  • Analyze the competitive factors, competitors’ market shares, product capabilities, and supply chain structures.

IndustryARC Research Best Practices

The Biosimilars market size is evaluated based on the number of products per organization type along with the varying price points pertaining to specific applications. These were identified as key informational conjectures for market estimation in 2017.

The Biosimilars market share is thoroughly checked against all data points that have been incorporated and rechecked against various data sources. Various C-level executives and key opinion leaders are contacted for verification of the data.

The Biosimilars market forecast and growth rate are achieved by applying the time series forecasting methodology on the various factors. The market forecast and growth rate are further backed with historical trends of the market along with a regressive mathematical model that assesses the value based on factors such as capital expenditure, equipment lifespan, R&D investments, and so on.

The Biosimilars market demand has been researched taking into account the prominent economies across the different geographic regions to understand their corresponding impact on the market.

The Biosimilars market drivers are evaluated for short-term, medium-term, and long-term based on the different market dynamics impacting the market.

The Biosimilars market challenges are evaluated for short-term, medium-term, and long-term based on the different market dynamics impacting the market.

The Biosimilars market trends have been analyzed taking into consideration the micro and macro trends prevalent in various geographies.

The Biosimilars market outlook provides a brief overview of the market performance and anticipated change in market dynamics. 

The Biosimilars market analysis also involves the identification of new companies that have entered the market scenario and their impact on the market dynamics in the future. 
1. Biosimilars Market – Market Overview
    1.1  Definitions and Scope
2. Biosimilars Market – Executive Summary
    2.1 Market Revenue, Market Size and Key Trends by Company
    2.2 Key trends by type 
    2.3 Key trends segmented by geography
3. Biosimilars Market – Industry Market Entry Scenario Premium
    3.1 Regulatory Framework Overview
    3.2 New Business and Ease of Doing business index
    3.3 Case studies of successful ventures
    3.4 Customer Analysis – Key companies Investment
4. Biosimilars Market – Market Forces
    4.1 Market Drivers
    4.2 Market Constraints
    4.3 Market Opportunities
    4.4 Porters five force model
        4.4.1 Bargaining power of suppliers
        4.4.2 Bargaining powers of customers
        4.4.3 Threat of new entrants
        4.4.4 Rivalry among existing players
        4.4.5 Threat of substitutes 
5. Biosimilars Market – By Product Type (Market Size -$Million/$Billion)
    5.1 Recombinant Non-Glycosylated Proteins
    5.2 Recombinant Glycosylated Proteins
    5.3 Peptides
6. Biosimilars Market – By Technology (Market Size -$Million/$Billion)
    6.1 Monoclonal Antibodies Technology
    6.2 Recombinant DNA Technology 
7. Biosimilars Market – By Application (Market Size -$Million/$Billion)
    7.1 Blood Disorders
    7.2 Oncology Diseases
    7.3 Chronic and Autoimmune Diseases 
    7.4 Growth Hormone Deficiency
    7.5 Others
8. Biosimilars Market – By Geography (Market Size -$Million/$Billion)
    8.1 North America
        8.1.1 U.S
        8.1.2 Canada
        8.1.3 Mexico
    8.2 Europe
        8.2.1 UK
        8.2.2 Germany
        8.2.3 France
        8.2.4 Italy
        8.2.5 Spain
        8.2.6 Russia
        8.2.7 Rest of Europe
    8.3 Asia-Pacific
        8.3.1 China
        8.3.2 Japan
        8.3.3 South Korea
        8.3.4 India
        8.3.5 Australia
        8.3.6 Taiwan
        8.3.7 Rest of APAC
    8.4 Rest of the World
        8.4.1 South America
        8.4.2 Middle East
        8.4.3 Africa
9. Biosimilars Market – Entropy
10. Biosimilars Market – Company Analysis
    10.1 Market Share, Company Revenue, Products, M&As, Developments
    10.2 Company 1
    10.3 Company 2
    10.4 Company 3
    10.5 Company 4
    10.6 Company 5
    10.7 Company 6
    10.8 Company 7
    10.9 Company 8
    10.10  Company 9
    10.11  Company 10 and more
"*Financials of private companies would be provided on a best-efforts basis "
List of Tables

Table 1 Biosimilars Market Competitor Analysis
Table 2 Biosimilars Market Revenue ($m), By Company, 2018
Table 3 Biosimilars Market: Startup Companies Scenario, By Company 
Table 4 Major Government Regulations
Table 5 The Ease of Doing Business Index: Top Countries
Table 6 Biosimilars Market: Patent Status of Some Innovator Biologics
Table 7 Biosimilars Market Revenue, By Region, 2018–2023 ($m)
Table 8 Biosimilars Market, Key Company list by Country


List of Figure

Figure 1 Biosimilars Market Value Share – By Geography 2018, 2023 (%)
Figure 2 Biosimilars Market CAGR (%) – By Geography
Figure 3 Biosimilars Market Value Share – Application 2018, 2023 (%)
Figure 4 Biosimilars Market CAGR (%) – By Application
Figure 5 Novartis International AG
Figure 6 Pfizer Inc.
Figure 7 Celltrion
Figure 8 Teva Pharmaceutical Industries Ltd.
Figure 9 EPS, By Company, 2015–2018 ($/Share)
Figure 10 Biosimilars Market, Number of Patents, 2014–2018*
Figure 11 Biosimilars Market, Number of Patents, By Country, 2014–2018*
Figure 12 Biosimilars Market: Startup Companies
Figure 13 Biosimilars Market: Consortium
Figure 14 Biosimilars Market, Value Chain Analysis
Figure 15 Biosimilars Market Life Cycle, 2018–2023
Figure 16 Biosimilars Market Segmentation – By Type
Figure 17 Biosimilars Market CAGR (%), By Type, 2018–2023
Figure 18 Biosimilars Market Segmentation - By Technology
Figure 19 Biosimilars Market CAGR (%), By Technology, 2018–2023
Figure 20 Biosimilars Market Segmentation – By Application
Figure 21 Biosimilars Market CAGR (%) – By Application, 2018–2023
Figure 22 Type of Leukemia in Canada,  1992-2008
Figure 23 Estimated Cancer Cases in Canada (%), 2018
Figure 24 Biosimilars Market Entropy Share, By Strategies, 2016-2019* (%)
Figure 25 Biosimilars Market Entropy, By Total Number of Developments, 2016-2019* 
Figure 26 Biosimilars Market Share – By Company, 2018 (%)